Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+3.9%
5Y CAGR+8.6%
Year-over-Year Change
Earnings before interest, taxes, depreciation, and amortization
3Y CAGR
+3.9%/yr
vs +58.3%/yr prior
5Y CAGR
+8.6%/yr
Recent deceleration
Acceleration
-54.4pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.5x
Solid growth
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $4.97B | +921.6% |
| 2024 | $486.30M | -89.4% |
| 2023 | $4.61B | +3.8% |
| 2022 | $4.44B | +52.0% |
| 2021 | $2.92B | -11.2% |
| 2020 | $3.28B | +110.5% |
| 2019 | $1.56B | +120.8% |
| 2018 | $706.78M | +584.5% |
| 2017 | $103.26M | +36.8% |
| 2016 | $75.46M | - |